A Phase 2 interventional study of brivekimig and Placebo in Crohn's Disease, sponsored by Sanofi. Recruiting at 78 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Crohn Disease by Sanofi — 4 open to participants now, 4 under way, 2 of them phase 3. Crohn Disease · Sanofi.
Among the 14 studies in Crohn Disease by Sanofi, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 2, and was the 10th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 14 studies in Crohn Disease by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Australia, Austria and 24 more countries
Ages 16–80
Sanofi · Sites in United States, Argentina, Australia and 33 more countries
Ages 16–80
Sanofi
Ages 18–65
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 102 across the 14 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
1 of the studies in Crohn Disease by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06958536SanofiA Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease | 2026-12-17 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Crohn Disease by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with following ongoing known complications of CD:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive brivekimig dose regimen A
Drug: brivekimig
Participants will receive brivekimig dose regimen B
Drug: brivekimig
Participants will receive placebo
Drug: Placebo
Route of Administration: Subcutaneous
Also known as: SAR442970
Route of Administration: Subcutaneous
Percentage of participants who achieve endoscopic response at Week 16
Endoscopic response is defined as decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Time frame: From Baseline to Week 16
Percentage of participants who achieve clinical remission based on Crohn's Disease Activity Index (CDAI) at Week 16
CDAI clinical remission is defined as CDAI score \<150. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.
Time frame: At Week 16
Percentage of participants who achieve PRO-2 (Patient Reported Outcome) clinical remission at Week 16
PRO-2 clinical remission is defined as using the average daily Stool Frequency (SF) ≤3 and not worse than baseline and average daily AP ≤1 and not worse than baseline.
Time frame: At Week 16
Percentage of participants who achieve endoscopic remission based on centrally read SES-CD at Week 16
Endoscopic remission is defined as SES-CD ≤4 and at least 2 point reduction versus baseline and no subscore \>1 in any individual variable based on central reading.
Time frame: At Week 16
Percentage of participants who achieve both clinical remission based on CDAI score and endoscopic response based on SES- CD at Week 16
CDAI clinical remission is defined as CDAI score \<150, endoscopic response is defined as a decrease in SES-CD \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.
Time frame: At Week 16
Percentage of participants who achieve CDAI clinical response at Week 16
CDAI clinical response is defined as reduction of CDAI ≥100 points from baseline.
Time frame: At Week 16
Change from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score
The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item instrument assessing health-related quality of life in IBD patients across four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Each question evaluates experiences over the previous two weeks on a 7-point Likert scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224, with higher scores indicating better quality of life. Both domain-specific and overall scores can be calculated.
Time frame: From Baseline to Week 16
Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score
The FACIT-F questionnaire assesses fatigue associated with anemia through 13 fatigue-related questions. Each item is scored on a 5-point Likert scale (0="not at all" to 4="very much"), with total scores ranging from 0 to 52. High scores represent less fatigue. For Crohn's Disease patients, a 7-10 point improvement on the FACIT-F total score may represent meaningful improvements.
Time frame: From Baseline to Week 16
On-treatment serum concentrations of brivekimig at predefined timepoints
Time frame: Up to End of Study (approximately 164 weeks)
Number and percentage of participants with any Treatment Emergent Adverse Events (TEAEs) during induction, maintenance and Long-term Extension (LTE) treatment period
Time frame: Up to End of Study (approximately 164 weeks)
Number and percentage of participants with any TEAEs during open-label treatment period
Time frame: Up to Week 52
Incidence of Anti-drug Antibodies (ADAs) over time
Time frame: Up to End of Study (approximately 164 weeks)
Percentage of participants who achieve endoscopic remission based on centrally read SES-CD at Week 52
Endoscopic remission is defined as SES-CD ≤4 and at least 2 point reduction versus baseline and no subscore \>1 in any individual variable based on central reading.
Time frame: At Week 52
Percentage of participants who achieve endoscopic response at Week 52
Endoscopic response is defined as decrease in SES-CD \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.
Time frame: At Week 52
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 18 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivekimig